Literature DB >> 22011316

Study of quercetin-loaded liposomes as potential drug carriers: in vitro evaluation of human complement activation.

Ana Paula Landi-Librandi1, Taís Nader Chrysostomo, Ana Elisa Caleiro Seixas Azzolini, Cleni Mara Marzocchi-Machado, Carlos Alberto de Oliveira, Yara Maria Lucisano-Valim.   

Abstract

Liposomes have been employed as potential drug carriers. However, after their in vivo administration, they can be destabilized by proteins of complement system, contributing to the clearance of vesicles from blood circulation. Antioxidant flavonoids such as quercetin have been reported to be beneficial to human health, but their low water solubility and bioavailability limit their enteric administration. Therefore, the development of appropriate flavonoid-carriers could be of great importance to drug therapy. The aim of the present study was to evaluate the activation of human complement system proteins by liposomes composed of soya phosphatidylcholine (SPC) and cholesterol (CHOL) or cholesteryl ethyl ether (CHOL-OET) loaded with quercetin or not. The consumption of complement, via classical (CP) and alternative (AP) pathways, by different vesicles was evaluated using a hemolytic assay and quantitative determination of iC3b and natural antibodies deposited on empty liposomal surfaces by ELISA. The main results showed that empty liposomes composed of large amounts of CHOL consumed more complement components than the others for both CP and AP. Furthermore, replacement of CHOL with CHOL-OET reduced complement consumption via both CP and AP. Incorporation of quercetin did not change CP and AP consumption. Deposition of iC3b, IgG and IgM in vesicles composed of SPC:CHOL-OET at a molar ratio of 1.5:1 was lower compared to the others. Taken together, these observations suggest that liposomes composed of SPC:CHOL-OET at a molar ratio of 1.5:1 are the most appropriate among the vesicles studied herein to be used as a drug carrier system in further investigations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22011316     DOI: 10.3109/08982104.2011.615321

Source DB:  PubMed          Journal:  J Liposome Res        ISSN: 0898-2104            Impact factor:   3.648


  5 in total

1.  Clinical Trials of Liposomes in Children's Anticancer Therapy: A Comprehensive Analysis of Trials Registered on ClinicalTrials.gov.

Authors:  Zhaosong Feng; Yuyang Gu; Mengping Yuan; Renzhong Xiao; Zhenghua Fei
Journal:  Int J Nanomedicine       Date:  2022-04-26

2.  Immunomodulating action of the 3-phenylcoumarin derivative 6,7-dihydroxy-3-[3',4'-methylenedioxyphenyl]-coumarin in neutrophils from patients with rheumatoid arthritis and in rats with acute joint inflammation.

Authors:  Lucinéia Reuse Albiero; Micássio Fernandes de Andrade; Larissa Fávaro Marchi; Ana Paula Landi-Librandi; Andréa Silva Garcia de Figueiredo-Rinhel; Camila Andressa Carvalho; Luciana Mariko Kabeya; Renê Donizeti Ribeiro de Oliveira; Ana Elisa Caleiro Seixas Azzolini; Mônica Tallarico Pupo; Flávio da Silva Emery; Yara Maria Lucisano-Valim
Journal:  Inflamm Res       Date:  2019-11-30       Impact factor: 4.575

Review 3.  Surface Functionalization and Targeting Strategies of Liposomes in Solid Tumor Therapy: A Review.

Authors:  Muhammad Kashif Riaz; Muhammad Adil Riaz; Xue Zhang; Congcong Lin; Ka Hong Wong; Xiaoyu Chen; Ge Zhang; Aiping Lu; Zhijun Yang
Journal:  Int J Mol Sci       Date:  2018-01-09       Impact factor: 5.923

4.  Comparative Interaction Studies of Quercetin with 2-Hydroxyl-propyl-β-cyclodextrin and 2,6-Methylated-β-cyclodextrin.

Authors:  Vasiliki Vakali; Michail Papadourakis; Nikitas Georgiou; Nikoletta Zoupanou; Dimitrios A Diamantis; Uroš Javornik; Paraskevi Papakyriakopoulou; Janez Plavec; Georgia Valsami; Andreas G Tzakos; Demeter Tzeli; Zoe Cournia; Thomas Mauromoustakos
Journal:  Molecules       Date:  2022-08-26       Impact factor: 4.927

5.  Development and optimization of quercetin-loaded PLGA nanoparticles by experimental design.

Authors:  Lucia Ruxandra Tefas; Ioan Tomuţă; Marcela Achim; Laurian Vlase
Journal:  Clujul Med       Date:  2015-04-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.